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Introduction: Non-steroidal anti-inﬂammatory drugs’ (NSAIDs) symptomatic efﬁcacy in osteoarthritis
(OA) is often assessed in trials with a “ﬂare design”, i.e., including only patients with an increase in their
pain after stopping their usual treatment (NSAIDs or analgesic).
Objective: To evaluate the inﬂuence of the “ﬂare design” on NSAIDs apparent symptomatic efﬁcacy in OA.
Design: Search strategy: a systematic literature research was performed in Medline, EMBASE and The
Cochrane Register up to March 2009. All randomized controlled trials comparing NSAIDs vs placebo
symptomatic efﬁcacy in hip, knee, or digital OA were included.
Data collection and analysis: efﬁcacy was evaluated on pain (visual analog scale), and on function
(Western Ontario and McMaster Universities OA index or Lequesne index). The magnitude of the
treatment effect was evaluated by calculating Cohen’s effect size (ES). Meta-analysis of ES according to
ﬂare design yes/no was performed.
Results: Among the 343 identiﬁed studies, 33 (20,915 patients) were included: 27 (18,667 patients) vs 6
(2248 patients) respectively in the group with vs without “ﬂare design”. Populations were comparable in
each group. ESs were, for pain, 0.66 (95% conﬁdence interval, 0.71 to 0.61), vs 0.45 (0.54 to
0.36) in the ﬂare design vs “no ﬂare design” group, and for function, 0.50 (0.55 to 0.44) vs 0.25
(0.36 to 0.14) respectively.
Conclusion: Our study suggests that the ﬂare design used in clinical trials evaluating NSAIDs results in
a treatment effect of higher magnitude. These results should be considered when designing a trial and/or
interpreting the results of a trial.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common rheumatic disease
leading to severe disability1. Approximately 10% of the population
aged over 60 years is affected by OA and the prevalence increases
over 30% for those 70 years old2. Hands, hips, knees and the spine
are the most commonly affected joints.
All the recently published guidelines state that optimal treat-
ment of knee and hip OA includes both pharmacological and non-
pharmacological interventions3,4. Among pharmacological agents,
ﬁrst line recommended treatment is oral acetaminophen followed
by non-steroidal anti-inﬂammatory drugs (NSAIDs). Therefore,axime Dougados, Service de
t Jacques, 75014 Paris, France.
. Dougados).
s Research Society International. PNSAIDs are seen as an important component of pharmacological
therapy for the management of OA.
Many clinical trials have assessed the efﬁcacy of NSAIDs.
However, most of these trials applied a speciﬁc study design, called
the “ﬂare design”. In ﬂare design trials, only patients who increased
in pain after stopping usual treatment (NSAIDs or analgesics),
during a screening phase, are entered into the NSAID trial. This ﬂare
designmay inﬂuence the observed symptomatic treatment effect of
NSAIDs. Intuitively, it appears that a study without ﬂare design
would reﬂect common daily practice better than ﬂare design.
Indeed, NSAIDs should be initiated either in symptomatic drug-
naïve patients, or after failure of analgesics or NSAIDs (but in this
speciﬁc case without a wash-out period between the discontinua-
tion of the previous NSAID and the initiation of the new one).
Therefore, the evaluation of the clinical relevance of results
reported in NSAIDs clinical trials should probably consider the issue
of the study design. In order to evaluate the potential inﬂuence ofublished by Elsevier Ltd. All rights reserved.
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we performed a systematic review with meta-analysis of all
randomized controlled trials comparing NSAIDs’ efﬁcacy vs placebo
in hip, knee and hand OA.Material and methods
Literature search
The objective of the search was to obtain all published
randomized placebo-controlled trials evaluating the symptomatic
efﬁcacy of NSAIDs in hip, knee or hand OA. Literature search was
performed by one assessor (ST) on all articles published between
1966 and March 2009 in different electronic databases (Medline
PUBMED, EMBASE and the Cochrane Controlled Trials Register for
randomized controlled trials). Papers in English or French were
eligible for inclusion. The search was conducted in PUBMED using
the following combination: [Osteoarthritis [Mesh] AND Anti-
Inﬂammatory Agents, Non-Steroidal [Pharmacological Action] AND
controlled trial AND placebo AND (Humans [Mesh]) AND (English
[lang] OR French [lang])].Inclusion criteria
Study design
All randomized controlled trials in parallel groups studying
NSAIDs vs placebo were included. Comparisons between different
NSAIDs or vs analgesics were excluded.
Study population
Patients fulﬁlling the American College of Rheumatology clas-
siﬁcation criteria for hip, hand or knee OA5e7.
Intervention
Any NSAID administered via an oral route as a treatment for OA-
related pain as soon as the evaluation was in comparison to
a placebo in a prospective randomized controlled trial.
Outcome measures
Articles were analyzed if an evaluation of pain and/or functional
status was available. The manuscripts with no interpretable results
(concerning pain and function) were excluded.
Pain intensity was extracted from the studies, as available, using
either a 100 mm visual analog scale (VAS) or the Western Ontario
and McMaster Universities OA index (WOMAC) subscale for pain,
linearly transformed to a 0e100 scale8. Physical function was
assessed by the WOMAC subscale for physical function or the
Lequesne index9, both were linearly transformed to a 0e100 scale.
Pre- and post-treatment data were extracted in both groups
(placebo and active). The post-treatment visit could range from 2 to
12 weeks. If several post-treatment visits were performed, we
a priori decided to extract data at week 3 or at the visit closest to
week 3.
Methodological quality
The articles that fulﬁlled inclusion criteria underwent quality
appraisal, performed by one single assessor (ST). To assess the
quality of randomized controlled trials, three parameters were
considered: (1) the impact factor of the journal in which the trial
was published, (2) the use of an intention-to-treat analysis for the
main analysis and (3) the Jadad scale; this scale contains two
questions for randomization and masking and one question eval-
uating the reporting of withdrawal and dropouts10. Each question
entails a yes or no response option. In total, ﬁve points can beawarded, with higher scores indicating superior quality. Data were
also extracted regarding funding sources for the studies.
Data extraction in included studies: Data extraction was per-
formed by one reviewer (ST), on the full texts, not blinded to author
and journal, using a predeﬁned extraction sheet available from the
authors. Apart from collecting the information required to calculate
the treatment effect size (ES), the following information were also
collected: date of the publication, NSAID characteristics and in
particular coxib vs conventional NSAID, duration of the trial, exis-
tence of a ﬂare design and in case of a ﬂare design the rigor of its
deﬁnition. In our study, a trial was considered as using a “ﬂare
design” in case the study design mentioned that the patients had to
take a symptomatic treatment before screening and that such
treatment had to be discontinued at screening visit. In case of a ﬂare
design, we further categorized the study in three categories with
regard to the rigor of the deﬁnition of this ﬂare design: the ﬁrst one
(less rigorous) in which a threshold in pain at baseline was only
required, the second one in which a threshold of increase in pain
between screening and baseline was required and ﬁnally the third
one and the most rigorous in which both a threshold of increase in
pain between screening and baseline and a threshold in pain at
baseline were required. Duration of the wash-out, deﬁnition of
“exacerbation” in symptoms and symptomatic treatment received
before the screening visit were also collected, if available.
Statistical analysis
To measure the magnitude of the treatment effect for pain
intensity and physical function, Cohen’s ES was calculated. The ES is
a standard way to determine the degree of improvement (or
otherwise) of a particular therapy after any placebo effect has been
accounted for. The ES is calculated as the ratio of the treatment
effect (changes in the active treatment group changes in the
placebo group) to the pooled standard deviation (SD) of the base-
line values. This calculation entails the use of means, for both
baseline and ﬁnal data (or baseline and change during study) with
a measure of variability such as SD at baseline11. Every effort was
made to calculate the ES in all studies. However, if no measure of
variability was given, the ES could not be extrapolated. By
convention, an ES< 0.2 is usually considered as trivial; >0.2e0.5 as
small; >0.5e0.8 as moderate; >0.8e1.2 as important; >1.2 as very
important. Minus or plus signs indicate direction of difference, not
magnitude of difference12. A t test for two means comparison was
calculated to compare ES.
Primary analysis examined the pooled ES of NSAIDs in ﬂare
design studies vs studies without ﬂare design, for pain and physical
function, using the inverse of the variancemethod. RevMan version
5.0 (Review Manager, Copenhagen, The Nordic Cochrane Centre,
2003) statistical software was used. Sensitivity analyses were
calculatedwithin subgroups of studies decided a priori to assess the
robustness of the main conclusions according to the time point of
evaluation, the deﬁnition of the ﬂare design, methodological
quality, NSAIDs type (COX II selective inhibitor or not) and date of
publication. Statistical heterogeneity was tested by Q test ([fx1]2)13.
All meta-analyses were carried out with use of random-effects
model in case of signiﬁcant heterogeneity.
Results
Included studies
The results of the article selection process are reported in Fig. 1.
From the 343 articles identiﬁed, 33 articles were included14e46.
Flare design was used in 27/33 (82%) studies. All studies were
funded by the pharmaceutical industry except two26,46. Studies
without ﬂare design were published between 1985 and 2006
The search via Medline, Cochrane database, Embase, Hand search
Identified 357 articles
Number of articles excluded after reading title 
and/or abstracts and/or the full text: 
- 34 articles had no placebo group 
- 49 articles had no available efficacy data 
- 69 articles studied tolerance 
- 71 articles were not randomised controlled trials 
- 86 articles studied other antalgics or did not 
study oral  NSAIDs treatment 
- 13 articles did not study hand, hip nor knee OA 
- 2 articles Mixed flare design with non flare 
design recruitment 
324 articles were excluded 
The number of articles selected for analysis was 
33 
Fig. 1. Selection of articles that evaluate NSAIDs symptomatic efﬁcacy in OA in placebo randomized controlled trials.
Table I
Baseline characteristics of studied population in placebo randomized controlled
trials evaluating NSAIDs efﬁcacy on OA
Studies with
“ﬂare design”
Studies without
“ﬂare design”
Total
Number of studies N¼ 27 N¼ 6 N¼ 33
Number of patients (%) 18,667 (90%) 2248 (10%) 20,915
Mean age (DS) 62.3 (2.5) 59.8 (1.7) 61.8
Female sex (ratio%) 13,942 (68%) 1697 (75%) 15,639 (70%)
OA location (N, %)
Knee 14,656 (78%) 1715 (73%) 16,371 (78%)
Hip 1969 (10%) 429 (22%) 2398 (11%)
Kneeþ hip 1388 (7%) 104 (5%) 1492 (7%)
Digital 654 (4%) 0 654 (4%)
Mean weight (kg) 83.8 (4) 79.1 (3) 82.4
Pain (0e100) 65.1 (16.6) 51.2 (21) 63.6
Function (0e100) 49.3 (15.1) 48.4 (19.8) 49.2
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between 1993 and 2007 (median date of publication: 2002).
Treatments before wash-out in ﬂare design studies were NSAIDs
and/or analgesics in 14 studies, exclusively NSAIDs in six, and were
not mentioned in seven. In non-ﬂare design studies, patients were
current NSAIDs or Acetaminophen users in two studies18,24 and
patients had symptomatic OA without any consideration about
previous symptomatic treatment in four studies40,42,43,45. Inclusion
criteria in non-ﬂare design studies were American College of
Rheumatology global functional class IeIII in three studies18,24,40 or
VAS> 35 mm or moderate pain in three studies42,43,45. Patients
were recruited in a primary care setting in two studies40,43 in the
non-ﬂare design studies and in one44 study in the ﬂare design
studies.
Quality of studies
The methodological quality was satisfactory: the mean impact
factor of the journal in which the different trials were published
was 4.1 (range 0.5e7.8): 3.5 for ﬂare design studies, and 4.6 for
studies without ﬂare design respectively. The mean SD Jadad
score was 3.71 vs 3.01.2 in groups with and without ﬂare
design respectively. All studies except two (94%) (one in each
group) used intention-to-treat analyses.
Study population
This systematic review included 20,915 patients suffering from
OA (Table I). There were 18,667 (90%) patients in the group with“ﬂare design” vs 2248 (10%) patients in the group without ﬂare
design. Themean age of these patients was 61.8 years, meanweight
was 82.4 kg, 70% were women. OA concerned knee (19 studies), hip
(four studies), knee and hip (eight studies) and hand (two studies).
Mean pain evaluated with VAS before treatment was higher in
group with ﬂare design than in the group without ﬂare design,
respectively 64.8 16.3 and 52.8 19.8 mm (Table I).Primary analysis: efﬁcacy of NSAIDs according to ﬂare design
Among the group with ﬂare design, 80% of NSAIDs tested were
coxibs. No coxibs were used in the group without ﬂare design.
Fig. 2. NSAIDs symptomatic efﬁcacy over placebo (ES) for pain and function in OA according to a ﬂare design of the trial.
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15 days. The mean trial duration was 37 days (range 14e91).
Studies were heterogeneous in the ﬂare design group: I2 was
70%. The detailed Revman analysis evaluating the ES for pain and
function with regard to the ﬂare design are presented in the
Supplementary data (Tables S1eS4) and are summarized in Fig. 2.
The efﬁcacy of NSAIDs in OA was conﬁrmed by an ES at least
moderate in both group (i.e., with or without ﬂare design) and both
evaluation criteria (i.e., pain or function).
For both domains (pain and function), the observed ES was
higher for trials using a ﬂare design than for those without a ﬂare
design: ES was0.66 [95% conﬁdence interval (CI),0.71,0.61] vs
0.45 [95% CI 0.54, 0.36] (P< 0.0001) for pain intensity in the
group with ﬂare design vs the group without ﬂare design respec-
tively. ES was 0.50 [95% CI 0.55, 0.44] vs 0.25 [95% CI 0.36,
0.14] (P< 0.0001) for function in the group with ﬂare design vs in
the group without ﬂare design respectively.
Subgroups analyzes
These analyzes were performed only for the domain pain and
are summarized in Table II. The main results observed, reported in
Fig. 2, seemed to have not been inﬂuenced by the quality of the trial
as suggested by a similar ES for pain in both groups (with or
without ﬂare design) with regard to the Jadad score (4 or <4).
Conversely, two interesting differences were observed with
regard to the deﬁnition of the ﬂare design and with regard to the
duration of the trial. Based on the data reported in Table II, it seemsTable II
Sub-group analysis of studies evaluating NSAIDs efﬁcacy in OA using ES over placebo for
Studies with ﬂare design
Number of
studies (patients)
Treatment period duration 3 weeks 9 (6515)
>3 weeks 18 (12152)
Jadad scorey (1e5) 1, 2, 3 13 (12755)
4, 5 14 (5912)
Flare sub-group* a 9 (8713)
b 6 (2597)
c 12 (7357)
) Flare sub-group: (1) pain threshold at baseline after a wash-out period following
symptomatic treatment resulting in a pre-deﬁned exacerbation in symptoms between scr
treatment resulting in both a pre-deﬁned exacerbation in symptoms between screening
y Jadad score¼ indicator of the quality of the trial from 1¼ low to 5¼ very high quali
z Values given are ES and [95% CI].that themore rigorouswas thedeﬁnitionof theﬂaredesign (i.e., pre-
deﬁnition of the exacerbation of the symptoms between screening
and baseline visits and pre-deﬁnition of a threshold for the baseline
visit value), the higher was the observed treatment effect.
More interestingly for daily practice, Table II suggests that the
plateau of efﬁcacy is achieved sooner when not using a ﬂare design
since the ES observed in this sub-groupwas similar in the studies of
2 weeks’ duration vs more than 2 weeks (0.45 [95% CI 0.62,
0.28] vs0.45 [95% CI0.56,0.34] respectively). Conversely the
ES seemed to increase in ﬂare design trials of more than 2 weeks’
duration vs trials of 2 weeks’ duration (0.70 [95% CI 0.76, 0.64]
vs 0.56 [95% CI 0.64, 0.49]).
In the studies with a ﬂare design, the treatment effect was
similar between COX II selective inhibitors and other NSAIDs.
Indeed, ES for pain intensity of COX II selective inhibitors and non-
selective NSAIDs were 0.65 [0.75, 0.60] and 0.66 [0.77,
0.55] respectively.
The majority of ﬂare design studies were published more
recently than non-ﬂare design studies (median time of publication:
2002 vs 1997). Our subgroup analysis performed according to the
date of publication showed results consistent with those of our
primary analysis. Indeed, considering papers published after 2002,
ES for pain intensity was 0.65 [0.70, 0.60] in studies with ﬂare
design, compared with 0.44 [0.57, 0.32] in the group without
ﬂare design. Consistently, considering studies published before
2002, ES for pain intensity was 0.65 [0.71, 0.59] in ﬂare design
studies, compared with 0.46 [0.59, 0.32] in the non-ﬂare
design studies.pain
Studies without ﬂare design
ESz for pain Number of
studies (patients)
ESx for pain
0.56 [0.64, 0.49] 2 (498) 0.45 [0.62, 0.28]
0.70 [0.76, 0.64] 4 (1750) 0.45 [0.56, 0.34]
0.62 [0.69, 0.55] 4 (1113) 0.46 [0.58, 0.33]
0.69 [0.76, 0.62] 2 (1135) 0.44 [0.57, 0.31]
0.54 [0.59, 0.49]
0.60 [0.72, 0.48]
0.79 [0.87, 0.71]
the previous symptomatic treatment; (2) wash-out period following the previous
eening and baseline visits; (3) wash-out period following the previous symptomatic
and baseline and a pain threshold at baseline.
ty.
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This study suggests that the use of a “ﬂare design” while con-
ducting studies in order to evaluate the symptomatic efﬁcacy in
NSAIDs in OA results in a higher treatment effect than studies
without this design.
The observed data has some implications not only for the
researchers in charge of developing new compounds but also for
the clinicians and patients wishing to evaluate adequately the
symptomatic treatment effect of a proposed treatment.
This study has strengths but also some limitations. The
systematic evaluation of all the published trials and the rigorous
methodology used in this study have obviously to be seen as
a strength. However, this analysis has some limitations that merit
consideration. The imbalance in the number of studies (27 with and
six without ﬂare design) might be considered as such a limitation.
However, the high number of patients in each group (i.e., more than
2200 in the “no ﬂare design” group) is probably a guarantee of the
veracity of the observed results. Another potential bias might be
due to the fact that we excluded studies without data permitting ES
calculation.
Potential publication bias inﬂuencing the process of locating and
selecting studies for inclusion cannot be excluded, since studies
with signiﬁcant results are more likely to be published. With the
exception of two studies, all the studies were industry funded and
there is evidence suggesting that industry-funded studies could
overestimate treatment effects. But this should not inﬂuence the
difference of efﬁcacy shown between ﬂare design and no ﬂare
design studies in this meta-analysis.
Included studies were almost all published in the past 10 years:
data permitting ES calculation were often not available in older
studies. As seen in the results, non-ﬂare design studies were pub-
lished earlier than ﬂare design studies. However, as shown in the
results section, publication time did not inﬂuence the evaluated
treatment effect. Flare recruitment generalization in studies eval-
uating NSAIDs efﬁcacy can be seen as studies design historical
development. Recent studies almost all use ﬂare recruitment
because of the suspected improvement of observed therapeutic
effect when using ﬂare. Nevertheless ﬂare recruitment in recent
years is not systematic: two non-ﬂare studies were published in
2006 and 200718,24.
All studies evaluating COX II selective inhibitors that were
included in this meta-analyses use a ﬂare design. This could
inﬂuence the difference shown between ES in ﬂare studies vs non-
ﬂare studies. Nevertheless, sensibility analyses in ﬂare studies
according to NSAIDs type showed no efﬁcacy difference between
both groups.
The question raised in this analysis (i.e., the inﬂuence of a ﬂare
design on the observed treatment effect) has already been
explored. Bjordal et al. showed that NSAIDs had better efﬁcacy on
pain related to OA in ﬂare design studies47. The originality of our
analysis was to assess the efﬁcacy of NSAIDs regarding to the
deﬁnition of ﬂare design. Indeed, we showed that the improvement
observed on NSAIDs differed according to ﬂare deﬁnition.
It is noteworthy that other designs have been described to
enhance the sensitivity detection of a drug effect48,49. However, our
systematic literature search did not ﬁnd other type of ﬂare designs
and in particular placebo run-in design.
Our results might be of interest to several categories of readers
and for many reasons. For the researcher in charge of designing
a placebo-controlled trial evaluating a potential new anti-inﬂam-
matory drug, one of the main objectives is to reduce the number of
patients who will have to be exposed to either an inactive
compound (e.g., placebo) or a potentially toxic drug (e.g., the new
anti-inﬂammatory drug). In this case, because of a higher treatmenteffect (i.e., a higher discriminant capacity), the ﬂare design should
be recommended since it will result in a smaller sample size.
For the patients, physicians, and payers in charge of evaluating
the clinical relevance of the observed results, our ﬁndings are of
great interest. The results reported in trials using a ﬂare design
might overestimate the treatment effect that will be observed in
daily practice. Obviously, in daily practice, at the individual level,
a ﬂare design is never used due to resistance from both the
physician and the patient. In daily practice, NSAIDs in OA are
initiated either in patients naïve of any symptomatic drug or
immediately after a previous non-effective symptomatic drug. The
single clinical situation in daily practice, which can be considered
quite close to a ﬂare design, is in fact the ﬂare observed after
a discontinuation of an efﬁcient treatment. In this case, because of
the concern of long-term toxicity of NSAIDs, patients suffering from
OA are usually stopping their treatment as soon as their symptoms
are disappearing. In such a case, a ﬂare can be observed and the
patient has to restart his/her therapy. In this particular situation,
the observed treatment effect might be of similar magnitude than
the one observed in ﬂare design trials.
Our study suggests also a kind of “dose ranging effect” of the
ﬂare design since the ES for pain was increasing with the detailed
deﬁnition of the ﬂare ranging from 0.54 for the trials in which the
ﬂare was only described as a pain threshold at baseline after
a wash-out period following the previous symptomatic treatment,
to 0.60 for the trials in which the ﬂare design was deﬁned by
a wash-out period following the previous symptomatic treatment
resulting in a pre-deﬁned exacerbation of symptoms between
screening and baseline, and to 0.79 for the trials in which the ﬂare
design was deﬁned as in the preceding group but with also a pre-
deﬁned pain threshold at baseline. These ﬁndings are not only
a strong argument in favor of the veracity of our ﬁndings, but also
can be of interest for the researcher in charge of conducting clinical
trials in this area.
Finally, our ﬁndings suggest that the time to reach the plateau of
efﬁcacy might differ with regard to the design of the study. In daily
practice, the patient/physician makes a “go/no go decision” in case
of a non-efﬁcient NSAID within 1 or 2 weeks. In ankylosing
spondylitis, one of the items of the Amor classiﬁcation criteria is
related to an improvement in symptoms within 48 h after NSAIDs’
intake. This pragmatic clinical approach is referring to the concept
of NSAID quick onset of action and a quick time to reach the plateau
of efﬁcacy. Our ﬁndings conﬁrm this clinical feeling, since in the “no
ﬂare design” studies, the ES for pain was similar whatever the
duration of the study. At variance, in the “ﬂare design” studies, the
ES was higher in studies of more than 2 weeks duration suggesting
a continuing improvement after week 2. These ﬁndings are difﬁcult
to interpret. One could suggest that pain and functional disability
observed in OA are related to either an inﬂammatory episode of the
disease or to a structural damage50,51. The ﬂare designmight recruit
probably more “inﬂammatory” patients because they are recruiting
patients in whom a previous anti-inﬂammatory has been efﬁcient
(before screening), and in whom a persistent inﬂammatory disease
has been demonstrated after discontinuing this previous anti-
inﬂammatory drug. Such a ﬂare design might result in a speciﬁc
phenotype of recruited patients (more inﬂammatory patients in the
ﬂare design trial and more “mechanical” patients in the no ﬂare
design). Apart from the fact that the ﬂare design results in a higher
treatment effect (anti-inﬂammatory drugs are probably more
active in case of “inﬂammatory” patients than in case of
“mechanical” patients), such a ﬂare design might also explain that
the plateau of efﬁcacy is achieved after a longer period of treat-
ment. This hypothesis will require further evaluation.
Because of the potential important implications of the present
ﬁndings, we strongly recommend to adequately evaluate the
S. Trijau et al. / Osteoarthritis and Cartilage 18 (2010) 1012e1018 1017symptomatic efﬁcacy of treatments in OA with regard to the use or
not of the ﬂare design, but also suggest that other studies should be
further conducted in order to conﬁrm and to better explain these
results.
Conﬂicts of interest
The authors declare no conﬂict of interest for the realization of the
study.
Acknowledgment
Funding: Abbott France organized a meta-analysis methods
workshop but played no further role in the project.
Supplementary data
Supplementary data associated with this article can be found in
online version at doi:10.1016/j.joca.2010.04.005.
References
1. Wright V. Osteoarthritis. Br Med J 1989;299:1476e7.
2. Felson DT. Epidemiology of hip and knee osteoarthritis.
Epidemiol Rev 1988;10:1e28.
3. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW,
Dieppe P, et al. Standing Committee for International Clinical
Studies Including Therapeutic Trials ESCISIT. EULAR Recom-
mendations 2003: an evidence based approach to the
management of knee osteoarthritis: report of a Task Force of
the Standing Committee for International Clinical Studies
Including Therapeutic Trials (ESCISIT). Ann Rheum Dis
2003;62:1145e55.
4. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J,
Gunther KP, et al. EULAR Standing Committee for International
Clinical Studies Including Therapeutics (ESCISIT). EULAR
evidence based recommendations for the management of hip
osteoarthritis: report of a task force of the EULAR Standing
Committee for International Clinical Studies Including Thera-
peutics (ESCISIT). Ann Rheum Dis 2005;64:669e81.
5. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D,
Brandt K, et al. The American College of Rheumatology criteria
for the classiﬁcation and reporting of osteoarthritis of the hip.
Arthritis Rheum 1991;34:505e14.
6. Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D,
Brandt K, et al. The American College of Rheumatology criteria
for the classiﬁcation and reporting of osteoarthritis of the
hand. Arthritis Rheum 1990;33:1601e10.
7. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al.
Development of criteria for the classiﬁcation and reporting of
osteoarthritis. Classiﬁcation of osteoarthritis of the knee.
Diagnostic and Therapeutic Criteria Committee of the
American Rheumatism Association. Arthritis Rheum
1986;29:1039e49.
8. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW.
Validation study of WOMAC: a health status instrument for
measuring clinically important patient relevant outcomes to
antirheumatic drug therapy in patients with osteoarthritis of
the hip or knee. J Rheumatol 1988;15:1833e40.
9. Lequesne M. Indices of severity and disease activity for oste-
oarthritis. Semin Arthritis Rheum 1991;20(Suppl 2):48e54.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,
Gavaghan DJ, et al. Assessing the quality of reports of
randomized clinical trials: is blinding necessary? Control Clin
Trials 1996;17:1e12.11. Practical meta-analysis. Lipsey MW. 2001;49:13.
12. Cohen J. A power primer. Psychol Bull 1992;112(1):155e9.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in
a meta-analysis. Stat Med 2002;21:1539e58.
14. Bingham III CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S,
et al. Efﬁcacy and safety of etoricoxib 30 mg and celecoxib
200 mg in the treatment of osteoarthritis in two identically
designed, randomized, placebo-controlled, non-inferiority
studies. Rheumatology (Oxford) 2007;46:496e507.
15. Wittenberg RH, Schell E, Krehan G, Maeumbaed R, Runge H,
Schlüter P, et al. First-dose analgesic effect of the cyclo-oxy-
genase-2 selective inhibitor lumiracoxib in osteoarthritis of
the knee: a randomized, double-blind, placebo-controlled
comparison with celecoxib [NCT00267215]. Arthritis Res Ther
2006;8:R35.
16. Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A,
Petruschke RA, et al. Efﬁcacy and safety of rofecoxib 12.5 mg
and celecoxib 200 mg in two similarly designed osteoarthritis
studies. Curr Med Res Opin 2006;22:199e210.
17. Schnitzer TJ, Kivitz AJ, Lipetz RS, Sanders N, Hee A. Comparison
of the COX-inhibiting nitric oxide donator AZD3582 and
rofecoxib in treating the signs and symptoms of osteoarthritis
of the knee. Arthritis Rheum 2005 Dec 15;53(6):827e37.
18. Svensson O, Malmenäs M, Fajutrao L, Roos EM, Lohmander LS.
Greater reduction of knee than hip pain in osteoarthritis
treated with naproxen, as evaluated by WOMAC and SF-36.
Ann Rheum Dis 2006;65(6):781e4.
19. Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S,
Sloan VS. Lumiracoxib is effective in the treatment of osteo-
arthritis of the knee: a prospective randomized 13-week study
versus placebo and celecoxib. Clin Rheumatol 2006;25
(1):42e53.
20. Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A,
Thurston H, et al. Efﬁcacy and tolerability of lumiracoxib
100 mg once daily in knee osteoarthritis: a 13-week,
randomized, double-blind study vs. placebo and celecoxib.
Curr Med Res Opin 2005;21(4):517e26.
21. Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT,
Wittmer BA, Protocol 071 Study Group, et al. Evaluation of the
comparative efﬁcacy of etoricoxib and ibuprofen for treatment
of patients with osteoarthritis: a randomized, double-blind,
placebo-controlled trial. Mayo Clin Proc 2005;80(4):470e9.
22. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Efﬁcacy
and tolerability of lumiracoxib in the treatment of osteoarthritis
of the knee: a 13-week, randomized, double-blind comparison
with celecoxib and placebo. Clin Ther 2005;27:64e77.
23. Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore A, et al.
Efﬁcacy and tolerability of lumiracoxib versus placebo in
patients with osteoarthritis of the hand. Clin Exp Rheumatol
2004;22(5):589e96.
24. Lohmander LS, McKeith D, Svensson O, Malmenäs M, Bolin L,
Kalla A, et al. STAR Multinational Study Group. A randomised,
placebo controlled, comparative trial of the gastrointestinal
safety and efﬁcacy of AZD3582 versus naproxen in osteoar-
thritis. Ann Rheum Dis 2005;64(3):449e56.
25. Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I,
et al. Efﬁcacy and safety of four doses of lumiracoxib versus
diclofenac in patients with knee or hip primary osteoarthritis:
a phase II, four-week, multicenter, randomized, double-blind,
placebo-controlled trial. Arthritis Rheum 2004;51:549e57.
26. Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, Najarian DK,
Dixon ME, , et alProtocol 085 Study Investigators. Efﬁcacy and
safety of rofecoxib 12.5 mg versus nabumetone 1000 mg in
patients with osteoarthritis of the knee: a randomized
controlled trial. J Am Geriatr Soc 2004;52:666e74.
S. Trijau et al. / Osteoarthritis and Cartilage 18 (2010) 1012e1018101827. Tannenbaum H, Berenbaum F, Reginster JY, Zacher J,
Robinson J, Poor G, et al. Lumiracoxib is effective in the
treatment of osteoarthritis of the knee: a 13 week, rando-
mised, double blind study versus placebo and celecoxib. Ann
Rheum Dis 2004;63:1419e26.
28. Case JP, Baliunas AJ, Block JA. Lack of efﬁcacy of acetamino-
phen in treating symptomatic knee osteoarthritis: a random-
ized, double-blind, placebo-controlled comparison trial with
diclofenac sodium. Arch Intern Med 2003;163:169e78.
29. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J,
Ko A, et al. Protocol 007 Study Group. Results of a randomized,
dose-ranging trial of etoricoxib in patients with osteoarthritis.
Rheumatology (Oxford) 2002;41:1052e61.
30. Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G,
Beaulieu A, et al. Efﬁcacy and tolerability proﬁle of etoricoxib
in patients with osteoarthritis: a randomized, double-blind,
placebo and active-comparator controlled 12-week efﬁcacy
trial. Curr Med Res Opin 2002;18(2):49e58.
31. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efﬁcacy and
safety of the COX-2 speciﬁc inhibitor valdecoxib in the
management of osteoarthritis of the hip: a randomized,
double-blind, placebo-controlled comparison with naproxen.
Osteoarthritis Cartilage 2002;10:290e6.
32. Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM,
Lefkowith JB, et al. Comparative efﬁcacy and safety of celecoxib
and naproxen in the treatment of osteoarthritis of the hip. J Int
Med Res. 2001;29(6):467e79.
33. Uzun H, Tuzun S, Ozaras N, Aydin S, Ozaras R, Dondurmaci S,
et al. The effect of ﬂurbiprofen and tiaprofenic acid on serum
cytokine levels of patients with osteoarthrosis. Acta Orthop
Scand 2001;72(5):499e502.
34. Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS. Compar-
ison of once-daily and twice-daily administration of celecoxib
for the treatment of osteoarthritis of the knee. Clin Ther
2001;23(2):213e27.
35. Lisse J, Espinoza L, Zhao SZ, Dedhiya SD, Osterhaus JT.
Functional status and health-related quality of life of elderly
osteoarthritic patients treated with celecoxib. J Gerontol A Biol
Sci Med Sci 2001;56(3):M167e75.
36. McKenna F, Borenstein D, Wendt H, Wallemark C,
Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the
management of osteoarthritis of the knee. Scand J Rheumatol
2001;30(1):11e8.
37. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M,
et al. A randomized trial of the efﬁcacy and tolerability of the
COX-2 inhibitor rofecoxib vs ibuprofen in patients with oste-
oarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch
Intern Med 2000 Jun 26;160(12):1781e7.
38. Zhao SZ, McMillen JI, Markenson JA, Dedhiya SD, Zhao WW,
Osterhaus JT, et al. Evaluation of the functional status aspects of
health-related quality of life of patients with osteoarthritis
treatedwithcelecoxib. Pharmacotherapy1999;19(11):1269e78.
39. Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F,
Weisman M, et al. Effect of speciﬁc COX-2 inhibition inosteoarthritis of the knee: a 6 week double blind, placebo
controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis
Pilot Study Group. J Rheumatol 1999;26(11):2438e47.
40. Davies GM, Watson DJ, Bellamy N. Comparison of the
responsiveness and relative effect size of the Western Ontario
and McMaster Universities Osteoarthritis Index and the short-
form Medical Outcomes Study Survey in a randomized, clinical
trial of osteoarthritis patients. Arthritis Care Res 1999;12
(3):172e9.
41. Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA,
Wallemark CB, et al. Diclofenac/misoprostol compared with
diclofenac in the treatment of osteoarthritis of the knee or hip:
a randomized, placebo controlled trial. Arthrotec Osteoar-
thritis Study Group. J Rheumatol 1998 Aug;25(8):1602e11.
42. Lund B, Distel M, Bluhmki E. A double-blind, randomized,
placebo-controlled study of efﬁcacy and tolerance of
meloxicam treatment in patients with osteoarthritis of the
knee. Scand J Rheumatol 1998;27(1):32e7.
43. Bourgeois P, Dreiser RL, Lequesne MG, Macciocchi A, Monti T.
Multi-centre double-blind study to deﬁne the most favourable
dose of nimesulide in terms of efﬁcacy/safety ratio in the
treatment of osteoarthritis. Eur J Rheumatol Inﬂamm 1994;14
(2):39e50.
44. Dreiser RL, Gersberg M, Thomas F, Courcier S. Ibuprofen
800 mg in the treatment of arthrosis of the ﬁngers or
rhizarthrosis (In French). Rev Rhum Ed Fr 1993 Nov 30;60
(11):836e41.
45. Lee P, Davis P, Prat A. The efﬁcacy of diﬂunisal in osteoarthritis
of the knee. A Canadian Multicenter Study. J Rheumatol
1985;12(3):544e8.
46. Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the
treatment of osteoarthritis of the hip. Arthritis Rheum 1994;37
(4):529e36.
47. Bjordal JM, Klovning A, Ljunggren AE, Slørdal L. Short-term
efﬁcacy of pharmacotherapeutic interventions in osteoar-
thritic knee pain: a meta-analysis of randomised placebo-
controlled trials. Eur J Pain 2007 Feb;11(2):125e38.
48. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched
enrolment with randomised withdrawal (EERW): time for
a new look at clinical trial design in chronic pain. Pain
2008;135:217e20.
49. Lemmens HJ, Wada DR, Munera C, Eltahtawy A, Stanski DR.
Enriched analgesics efﬁcacy studies: an assessment by clinical
trial simulation. Contemp Clin Trials 2006 Apr;27(2):165e73.
50. D’Agostino MA, Conaghan P, Le Bars M, Baron G, Grassi W,
Martin-Mola E, et al. EULAR report on the use of ultrasonog-
raphy in painful knee osteoarthritis. Part 1: prevalence of
inﬂammation in osteoarthritis. Ann Rheum Dis 2005;64
(12):1703e9.
51. Mazières B, Garnero P, Guéguen A, Abbal M, Berdah L,
Lequesne M, et al. Molecular markers of cartilage breakdown
and synovitis at baseline as predictors of structural progres-
sion of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum
Dis 2006;65(3):354e9.
